Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma
Status:
Withdrawn
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well ibrutinib plus rituximab and lenalidomide work in
treating elderly participants with newly diagnosed mantle cell lymphoma. Ibrutinib may stop
the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Immunotherapy with monoclonal antibodies, such as rituximab, may help the body's immune
system attack the cancer, and may interfere with the ability of tumor cells to grow and
spread. Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the
growth of cancer cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. Giving ibrutinib plus rituximab and lenalidomide may work
better in treating elderly participants with newly diagnosed mantle cell lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Celgene Janssen Scientific Affairs, LLC National Cancer Institute (NCI)